OLEMA PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.22 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2023-11-07
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-09-30 was $469.00K, a 65.67% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-09-30 was $1.37M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month |
|---|---|---|---|
| 2023-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.22M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$2.69M 10-Q · filed 2023-08-08 | ||
| 2022-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.28M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.92M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |